All-in-one CAR-T manufacturing using
next-generation technology

At ESGCT 2025, Limula presented data demonstrating integrated CAR-T manufacturing within a single platform, integrating T-cell selection, activation, transduction, and expansion.

Using Akadeum buoyancy-based CD3 negative selection, fresh PBMCs were isolated and expanded to clinically relevant doses while maintaining functional phenotype.

Key Highlights:

• >90% CD3⁺ purity with >97% viability and >60% recovery from fresh PBMCs
• 94-fold expansion in 7 days, increasing from 12 million to 1.1 billion viable T cells
• Successful lentiviral transduction with functional CD19 CAR-T tumor killing
  

Download the poster to review the CAR-T workflow and performance data 👉